Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bastian von Tresckow

Showing results (1-10 of 168) with videos related to

Pageof 17
Sort By:
Current Opinion in Oncology|August 15, 2013
Refractory Hodgkin lymphomaBastian von Tresckow, Andreas Engert
Current Hematologic Malignancy Reports|May 14, 2011
The role of autologous transplantation in Hodgkin lymphomaBastian von Tresckow, Andreas Engert
Leukemia & Lymphoma|March 21, 2017
Novel agents in classical Hodgkin lymphomaSven Borchmann, Bastian von Tresckow
Expert Review of Hematology|November 14, 2012
The emerging role of PET in Hodgkin lymphoma patients receiving autologous stem cell transplantBastian von Tresckow, Andreas Engert
Haematologica|May 28, 2026
On closing the gap: anti-PD-1-based salvage in relapsed/refractory classical Hodgkin lymphoma. Comment on: "Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma"Hishan Tharmaseelan, Bastian Von Tresckow
Expert Opinion on Emerging Drugs|April 23, 2014
An update on emerging drugs for Hodgkin lymphomaBastian von Tresckow, Volker Diehl
Blood|January 17, 2025
Combined targeted modality in cHL: a risky bet?Paul J Bröckelmann, Bastian von Tresckow
British Journal of Haematology|June 8, 2020
Risk stratification and prognostic biomarkers in relapsed Hodgkin lymphomaPaul J Bröckelmann, Bastian von Tresckow
Blood|August 21, 2025
Checkpoint-primed allo-HCT in HL: cure gains, risk remainsPaul J Bröckelmann, Bastian von Tresckow
Seminars in Hematology|August 7, 2016
Treatment of relapsed and refractory Hodgkin LymphomaBastian von Tresckow, Craig H Moskowitz
Pageof 17

Showing results (1-10 of 168) with videos related to

Sort By:
Pageof 17
Current Opinion in Oncology|August 15, 2013
Refractory Hodgkin lymphomaBastian von Tresckow, Andreas Engert
Current Hematologic Malignancy Reports|May 14, 2011
The role of autologous transplantation in Hodgkin lymphomaBastian von Tresckow, Andreas Engert
Leukemia & Lymphoma|March 21, 2017
Novel agents in classical Hodgkin lymphomaSven Borchmann, Bastian von Tresckow
Expert Review of Hematology|November 14, 2012
The emerging role of PET in Hodgkin lymphoma patients receiving autologous stem cell transplantBastian von Tresckow, Andreas Engert
Haematologica|May 28, 2026
On closing the gap: anti-PD-1-based salvage in relapsed/refractory classical Hodgkin lymphoma. Comment on: "Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma"Hishan Tharmaseelan, Bastian Von Tresckow
Expert Opinion on Emerging Drugs|April 23, 2014
An update on emerging drugs for Hodgkin lymphomaBastian von Tresckow, Volker Diehl
Blood|January 17, 2025
Combined targeted modality in cHL: a risky bet?Paul J Bröckelmann, Bastian von Tresckow
British Journal of Haematology|June 8, 2020
Risk stratification and prognostic biomarkers in relapsed Hodgkin lymphomaPaul J Bröckelmann, Bastian von Tresckow
Blood|August 21, 2025
Checkpoint-primed allo-HCT in HL: cure gains, risk remainsPaul J Bröckelmann, Bastian von Tresckow
Seminars in Hematology|August 7, 2016
Treatment of relapsed and refractory Hodgkin LymphomaBastian von Tresckow, Craig H Moskowitz
Pageof 17